SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00000838

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Phase II, Randomized Study of the Antiviral Activity and Resistance Interactions of Lamivudine (3TC) in Combination With Zidovudine (AZT), Stavudine (d4T), or Didanosine (ddI) Versus Monotherapy With ddI or d4T in HIV-Infected Individuals With 200 - 600 CD4+ Cells/mm3 and No Previous Nucleoside Experience

To evaluate the efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine (AZT), stavudine (d4T), or didanosine (ddI) in comparison with d4T or ddI monotherapy in HIV-infected patients with no prior nucleoside therapy. 3TC may be uniquely effective in combination with AZT due to the interaction of AZT and 3TC resistance mutations. One explanation is that the M184V mutation, which confers resistance to 3TC, suppresses AZT resistance. This benefit of 3TC may not extend to combination therapy with other nucleoside analogs.

NCT00000838 HIV Infections
MeSH:HIV Infections

4 Interventions

Name: Lamivudine

Type: Drug

Name: Stavudine

Type: Drug

Name: Zidovudine

Type: Drug

Name: Didanosine

Type: Drug



Purpose: Treatment


There is one SNP

SNPs


1 M184V

One explanation is that the M184V mutation, which confers resistance to 3TC, suppresses AZT resistance. --- M184V ---



HPO Nodes